EPLIVANSERIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H21FN2O2
Molecular Weight	328.3806
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)C2=CC=CC=C2F

InChI

InChIKey=VAIOZOCLKVMIMN-PRJWTAEASA-N

InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800001948 | https://www.ncbi.nlm.nih.gov/pubmed/1501121 | https://www.ncbi.nlm.nih.gov/pubmed/23616706

Eplivanserin (SR 46349) is an antagonist of serotonin 2A receptor. Eplivanserin was previously in development by Sanofi-aventis in an effort to educate the public regarding this new mechanism of action for sleep aids. Eplivanserin was reviewed by the FDA as a potential treatment for patients with chronic insomnia, but the FDA requested additional information regarding benefit-risk and development of the drug has been discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18673166 \| https://www.ncbi.nlm.nih.gov/pubmed/1501121	Antagonist 2778

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Phase III study: 5 mg/day for 12 weeks

Route of Administration: Oral

Name

Type

Language

EPLIVANSERIN

Official Name

English

SR-46349

Code

English

2-PROPEN-1-ONE, 1-(2-FLUOROPHENYL)-3-(4-HYDROXYPHENYL)-, O-(2-(DIMETHYLAMINO)ETHYL)OXIME, (1Z,2E)-

Common Name

English

EPLIVANSERIN [USAN]

Common Name

English

eplivanserin [INN]

Common Name

English

SR46349

Code

English

4-[(1E,3Z)-3-{[2-(Dimethylamino)ethoxy]imino}-3-(2-fluorophenyl)prop-1-enyl]phenol

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66885